Hepatotoxicity by Drugs: The Most Common Implicated Agents

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Feb 11

PMID 26861310

Citations 99

Authors

Einar S Bjornsson

Affiliations

Soon will be listed here.

Abstract

Idiosyncratic drug-induced liver injury (DILI) is an underreported and underestimated adverse drug reaction. Information on the documented hepatotoxicity of drugs has recently been made available by a website that can be accessed in the public domain: LiverTox (http://livertox.nlm.nih.gov). According to critical analysis of the hepatotoxicity of drugs in LiverTox, 53% of drugs had at least one case report of convincing reports of liver injury. Only 48 drugs had more than 50 case reports of DILI. Amoxicillin-clavulanate is the most commonly implicated agent leading to DILI in the prospective series. In a recent prospective study, liver injury due to amoxicillin-clavulanate was found to occur in approximately one out of 2300 users. Drugs with the highest risk of DILI in this study were azathioprine and infliximab.

Citing Articles

MAPK13 phosphorylates PHGDH and promotes its degradation via chaperone-mediated autophagy during liver injury.

Xing R, Liu R, Man Y, Liu C, Zhang Y, Gao H Cell Discov. 2025; 11(1):15.

PMID: 39962071 PMC: 11832932. DOI: 10.1038/s41421-024-00758-w.

Certolizumab-Induced Liver Injury in Ankylosing Spondylitis: A Case Report and Causality Assessment.

Bensaghir I, Tahiri L, Farih S, Rkain H, Allali F Cureus. 2024; 16(8):e66569.

PMID: 39258044 PMC: 11385431. DOI: 10.7759/cureus.66569.

Ramucirumab in second‑line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation.

Kimura K, Katata Y, Umeda Y, Tanaka T, Yano S, Yoshida K Oncol Lett. 2024; 28(3):439.

PMID: 39081965 PMC: 11287105. DOI: 10.3892/ol.2024.14572.

Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents.

Katolkar U, Surana S Curr Protein Pept Sci. 2024; 25(10):753-779.

PMID: 38919003 DOI: 10.2174/0113892037307940240606075208.

Synthesis of Thiazolidin-4-Ones Derivatives, Evaluation of Conformation in Solution, Theoretical Isomerization Reaction Paths and Discovery of Potential Biological Targets.

Georgiou N, Karta D, Cheilari A, Merzel F, Tzeli D, Vassiliou S Molecules. 2024; 29(11).

PMID: 38893334 PMC: 11173912. DOI: 10.3390/molecules29112458.

References

Perez Gutthann S, Garcia Rodriguez L . The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology. 1993; 4(6):496-501. View

Bjornsson E, Hoofnagle J . Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology. 2015; 63(2):590-603. DOI: 10.1002/hep.28323. View

Garcia Rodriguez L, Ruigomez A, Jick H . A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy. 1997; 17(4):721-8. View

Vergis E, Paterson D, Singh N . Indinavir-associated hepatitis in patients with advanced HIV infection. Int J STD AIDS. 1998; 9(1):53. DOI: 10.1258/0956462981920883. View

Bjornsson E, Olsson R . Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005; 42(2):481-9. DOI: 10.1002/hep.20800. View

Andrade R, Lucena M, Fernandez M, Pelaez G, Pachkoria K, Garcia-Ruiz E . Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2):512-21. DOI: 10.1016/j.gastro.2005.05.006. View

Pavel S, Burty C, Alcaraz I, De La Tribonniere X, Baclet V, Ajana F . Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS. 2007; 21(2):268-9. DOI: 10.1097/QAD.0b013e328011aa35. View

Chalasani N, Fontana R, Bonkovsky H, Watkins P, Davern T, Serrano J . Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135(6):1924-34, 1934.e1-4. PMC: 3654244. DOI: 10.1053/j.gastro.2008.09.011. View

Papay J, Clines D, Rafi R, Yuen N, Britt S, Walsh J . Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009; 54(1):84-90. DOI: 10.1016/j.yrtph.2009.03.003. View

10.

Andrade R, Robles M, Lucena M . Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf. 2009; 8(6):709-14. DOI: 10.1517/14740330903397378. View

11.

Agarwal V, McHutchison J, Hoofnagle J . Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010; 8(5):463-70. PMC: 3901223. DOI: 10.1016/j.cgh.2010.02.008. View

12.

Suzuki A, Andrade R, Bjornsson E, Lucena M, Lee W, Yuen N . Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010; 33(6):503-22. DOI: 10.2165/11535340-000000000-00000. View

13.

Devarbhavi H, Dierkhising R, Kremers W, Sandeep M, Karanth D, Adarsh C . Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010; 105(11):2396-404. DOI: 10.1038/ajg.2010.287. View

14.

Bjornsson E, Bergmann O, Bjornsson H, Kvaran R, Olafsson S . Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7):1419-25, 1425.e1-3. DOI: 10.1053/j.gastro.2013.02.006. View

15.

Senior J . Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014; 37 Suppl 1:S9-17. PMC: 4212154. DOI: 10.1007/s40264-014-0182-7. View

16.

Bjornsson E, Jacobsen E, Einarsdottir R, Chalasani N . Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology. 2014; 148(2):269-73. DOI: 10.1053/j.gastro.2014.12.007. View

17.

de Abajo F, Montero D, Madurga M, Garcia Rodriguez L . Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58(1):71-80. PMC: 1884531. DOI: 10.1111/j.1365-2125.2004.02133.x. View

18.

Chalasani N, Bonkovsky H, Fontana R, Lee W, Stolz A, Talwalkar J . Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015; 148(7):1340-52.e7. PMC: 4446235. DOI: 10.1053/j.gastro.2015.03.006. View

19.

Danan G, Teschke R . RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015; 17(1). PMC: 4730261. DOI: 10.3390/ijms17010014. View

20.

Brau N, Leaf H, Wieczorek R, Margolis D . Severe hepatitis in three AIDS patients treated with indinavir. Lancet. 1997; 349(9056):924-5. DOI: 10.1016/S0140-6736(05)62700-6. View